ArticleMedComm2026
Optimizing Lung-molGPA-Directed Therapy for EGFR/ALK/ROS1-Wildtype Non-Small Cell Lung Cancer Brain Metastases: Survival Outcomes Analysis.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with non-small cell lung cancer (NSCLC) and brain metastases whose tumors lack EGFR, ALK, or ROS1 alterations have heterogeneous outcomes and limited evidence to guide treatment intensity. We assessed whether Lung-molGPA could stratify prognosis and inform treatment selection in this population. This retrospective two-center cohort included 811 patients with EGFR/ALK/ROS1-wild-type NSCLC treated between September 2013 and August 2022. Overall survival (OS) was evaluated using Kaplan-Meier methods and center-stratified multivariable Cox regression across three Lung-molGPA strata and treatment modalities. Median OS was 6.9 months (95% confidence interval [CI], 6.4-7.4) overall and 4.81 (4.20-5.30), 7.65 (6.73-8.40), and 16.00 (13.40-22.90) months in the Lung-molGPA 0-1.0, 1.5-2.0, and 2.5-3.0 groups, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.